New combo therapy shows promise for tough esophageal cancer
NCT ID NCT04229459
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests adding two drugs, nivolumab and cetuximab, to standard chemoradiation for people with a type of esophageal cancer that hasn't spread far. The goal is to see if this combination can make tumors disappear before surgery. The study involves 12 adults who haven't had prior treatment for this cancer, and they receive the drugs alongside radiation and chemotherapy, followed by surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rabin Medical Center
Petah Tikva, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads